ALTITUDE®NCT04567550
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 14 versions: 14 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 22 words
- Trial completed
- Study completion date changed from estimate of Dec 2026 to Jun 18, 2026
- Site details revised at 1 of 25 sites
- Minor Primary completion date changed from estimate of Jun 2026 to Jun 18, 2026v13
- Minor Primary completion date: Feb 2026 to Jun 2026
- Study completion date: Sep 2026 to Dec 2026
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 130 to confirmed 139
- Site details revised at 25 of 25 sites
Notable Primary completion date: May 2024 to Feb 2026v10 Show 11 more changesShow less
- Eligibility criteria expanded, about 148 words
- Primary endpoints: 1 to 2
- Enrollment target: 100 to 130
- Study sites: 21 to 25
- Study completion date: Oct 2024 to Sep 2026
- Interventions: RGX-314 Dose 1 (Genetic), RGX-314 Dose 2 (Genetic), RGX-314 Dose 3 (Genetic), Topical Steroid (Drug) to ABBV-RGX-314 Dose 1 (Genetic), ABBV-RGX-314 Dose 2 (Genetic), ABBV-RGX-314 Dose 3 (Genetic), ABBV-RGX-314 Dose 4 (Genetic), Aflibercept…
- Secondary endpoints: 4 to 39
- Study description expanded, about 60 words
- Study arms: 4 to 6
- Collaborators expanded, about 2 words
- Study title expanded, about 2 words
Show 8 earlier versionsHide 8 earlier versions
- Notable Lead sponsor: REGENXBIO Inc. to AbbVie
- Collaborators shortened, about 1 word
Notable Trial status: Active, Not Recruiting to Recruitingv8 Show 9 more changesShow less
- Enrollment target: 60 to 100
- Primary completion date: Jun 2023 to May 2024
- Study completion date: Jun 2023 to Oct 2024
- Interventions: RGX-314 Dose 1 (Genetic), RGX-314 Dose 2 (Genetic) to RGX-314 Dose 1 (Genetic), RGX-314 Dose 2 (Genetic), RGX-314 Dose 3 (Genetic), Topical Steroid (Drug)
- Secondary endpoints: 3 to 4
- Study description expanded, about 36 words
- Study sites revised (21)
- Study arms: 3 to 4
- Collaborators expanded, about 1 word
- Minor Trial status: Recruiting to Active, Not Recruiting
- Site details revised at 21 of 21 sites
- Notable Primary and study completion dates pushed to Jun 2023
- Site details revised at 3 of 21 sites
Notable Enrollment target: 40 to 60v5 Show 6 more changesShow less
- Primary completion date: May 2021 to Feb 2022
- Study sites: 7 to 21
- Study completion date: May 2022 to Jan 2023
- Interventions: RGX-314 Dose 1 (Biological), RGX-314 Dose 2 (Biological) to RGX-314 Dose 1 (Genetic), RGX-314 Dose 2 (Genetic)
- Secondary endpoints: details revised at 1 of 3 entries
- Study description expanded, about 61 words
- Minor Start date changed from estimate of Nov 2020 to Nov 20, 2020v4
- Minor Start date: Oct 2020 to Nov 2020
- Site details revised at 2 of 7 sites
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date: Sep 2020 to Oct 2020
- Site details revised at 7 of 7 sites
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Part 1: Proportion of participants achieving a 2-step or greater improvement in DR in the study eye per the ETDRS-DRSS on 4 widefield digital stereoscopic fundus photography at Week 48
Timeframe: At Week 48
Part 2: Mean change from baseline in Best Corrected Visual Acuity (BCVA) in the study eye at Week 54.
Timeframe: At Week 54
Secondary (39)
Part 1: Proportion of participants achieving an improvement in DR in the study eye per the ETDRS DRSS on 4 widefield digital stereoscopic fundus photography.
Part 1:Proportion of participants achieving a 0-step (no change) or greater improvement in DR in the study eye per the ETDRS DRSS on 4 widefield digital stereoscopic fundus photography.
Part 1:Proportion of participants with a worsening in DR in the study eye per the ETDRS-DRSS on 4 widefield digital stereoscopic fundus photography.
Part 1: Proportion of participants in the NPDR and PDR subgroups at baseline achieving an improvement or worsening in DR in the study eye per the ETDRS-DRSS on 4 widefield digital stereoscopic fundus photography.
Part 1: Proportion of participants graded as proliferative diabetic retinopathy (PDR) in the study eye at baseline achieving regression to nonproliferative diabetic retinopathy (NPDR) in the study eye.
Show 34 moreShow less
Part 1: Proportion of participants achieving a 0-step (no change) or greater improvement in DR in the study eye per the ETDRS-DRSS on 4-widefield digital stereoscopic fundus photography
Part 1: Proportion of participants with a worsening in DR in the study eye per the ETDRS-DRSS on 4 widefield digital stereoscopic fundus photography.
Part 1: Mean change from baseline in the study eye in ETDRS-DRSS severity steps at Week 12, Week 24, Week 36, and Week 48 and (CO participants) change from Week 48 at Week 54, Week 62, and Week 74
Part 1: Incidences of overall and ocular AEs
Part 1: Vector shedding analysis in serum, urine, and tears
Part 1: Proportion of participants who experience ocular inflammation in the study eye following Suprachoroidal Space (SCS) ABBV-RGX-314 administration.
Part 1: Proportion of participants requiring any additional intervention in the study eye for ocular diabetic complications
Part 1: Proportion of participants with any sight threatening ocular diabetic complications in the study eye based on duration of time to development of sight threatening ocular conditions
Part 1:Proportion of participants developing ocular diabetic complications in the study eye requiring treatment per SOC based on number of treatments received and duration of time from intervention to first treatment per SOC
Part 1: Proportion of participants developing ocular diabetic complications in the study eye requiring treatment per SOC based on duration of time from study intervention to first treatment and proportion of participants requiring more than 1 treatment
Part 1: Proportion of participants developing ocular diabetic complications in the study eye requiring surgical intervention per SOC based on duration of time from study intervention to surgical intervention
Part 1: Aqueous ABBV-RGX-314 TP concentration at assessed time points
Part 1: Serum ABBV-RGX-314 TP concentration at assessed time points
Part 2: Mean change from baseline in BCVA in the study eye over time
Part 2: Proportion of participants with improved BCVA in the study eye over time
Part 2: Proportion of participants with a worsening in DR in the study eye per the ETDRS-DRSS on 4 widefield digital stereoscopic fundus photography
Part 2: Proportion of participants achieving an improvement in DR in the study eye per the ETDRS-DRSS on 4 widefield digital stereoscopic fundus photography
Part 2: Proportion of participants achieving a 0-step (no change) or greater improvement in DR in the study eye per the ETDRS-DRSS on 4 widefield digital stereoscopic fundus photography
Part 2: Proportion of participants with a worsening in DR in the study eye per the ETDRS-DRSS on 4-widefield digital stereoscopic fundus photography
Part 2: Mean change from baseline in the study eye in ETDRS-DRSS severity steps at Week 22, Week 38, and Week 54 and (CO participants) change from Week 56 at Week 74 and Week 82
Part 2: Proportion of participants with an absence of CI-DME in the study eye
Part 2: Incidences of overall and ocular AEs
Part 2: Vector shedding analysis in serum, urine, and tears
Part 2: Proportion of participants who experience ocular inflammation in the study eye following SCS ABBV-RGX-314 administration
Part 2: Proportion of participants requiring any additional intervention in the study eye for ocular diabetic complications to Week 54 and (CO participants) Week 82
Part 2: Proportion of participants with any sight threatening ocular diabetic complications in the study eye based on duration of time to development of sight-threatening ocular conditions
Part 2: Proportion of participants developing ocular diabetic complications in the study eye requiring treatment per SOC based on number of treatments received and duration of time from study intervention to first treatment per SOC
Part 2: Proportion of participants developing ocular diabetic complications in the study eye requiring treatment per SOC based on duration of time from study intervention to first treatment and proportion of participants requiring more than 1 treatment
Part 2: Proportion of participants developing ocular diabetic complications in the study eye requiring surgical intervention per SOC
Part 2: Mean change from baseline in CST in the study eye on SD OCT at Week 30 and Week 54
Part 2: Mean change from Week 54 in CST in the study eye on SD OCT at Week 82 (Crossover participants)
Part 2: Proportion of participants achieving a reduction in CST in the study eye on SD-OCT at Week 30 and Week 54
Part 2: Aqueous ABBV-RGX-314 TP concentration at assessed time points
Part 2: Serum ABBV-RGX-314 TP concentration at assessed time points
Arms and interventions
Part 1: Observation Control ArmNo intervention
Observation Control
Part 1: ABBV-RGX-314 Treatment Arm (Dose 1)Experimental
ABBV-RGX-314 Dose 1
Part 1: ABBV-RGX-314 Treatment Arm (Dose 2)Experimental
ABBV-RGX-314 Dose 2
Part 1: ABBV-RGX-314 Treatment Arm (Dose 3) and Topical SteroidExperimental
ABBV-RGX-314 Dose 3 and Topical Steroid
Part 2: ABBV-RGX-314 Treatment Arm (Dose 4) and Topical SteroidExperimental
ABBV-RGX-314 Dose 4 and Topical Steroid
Part 2: Aflibercept ControlActive comparator
Control treatment arm
Genetic: ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, ABBV-RGX-314 Dose 3, ABBV-RGX-314 Dose 4
Drugs: Topical Steroid
Biologicals: Aflibercept
Sites
25 sites in 1 country